Pibrentasvir (ABT-530) is a novel and pan-genotypic HCV NS5A inhibitor with EC50 of 1.4-5.0 pM against HCV replicons containing NS5A genotypes 1-6.
Description :
Pibrentasvir (ABT-530) is a novel and pan-genotypic HCV NS5A inhibitor with EC50 of 1.4-5.0 pM against HCV replicons containing NS5A genotypes 1-6; demonstrates potent antiviral activity and acceptable safety during 3-day monotherapy in patients with HCV genotype 1 infection, with or without compensated cirrhosis.